[1] CHENG Z, LIU J, ZHONG JF, et al.Engineering CAR-T cells[J]. Biomarker Research, 2017, 5(1): 22. [2] BAO BY, TANG GG, WANG XW, et al.Research progress on new anti-tumor immunotherapy drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(8): 719-724. [3] HUANG Y, HOU TT, WEN HR, et al.Strategy and cases of preclinical safety evaluation of chimeric antigen receptor T cells products[J]. Chinese Journal of New Drugs(中国新药杂志), 2022, 31(8): 740-745. [4] HUANG Y, HOU TT, HUO Y.Overview of the development and application of animal models in non-clinical studies of CAR-T cell therapy products[J]. Chinese Pharmaceutical Affairs(中国药事), 2018, 32(7): 886-892. [5] LI YR, YANG C, LIU WD, et al.Seventy-three cases of suspected unexpected serious adverse reactions reports with chimeric antigen receptor T-cell therapy products[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(9): 600-606. [6] Center for Drug Evaluation. Technical Guidelines for Research and Evaluation of Cell Therapy Products (Trial)[EB/OL].(2017-12-22)[2022-04-20]. https://www.cde.org.cn/zdyz/domesticinfopage?zdyzIdCODE=452c529b299638297210fe4a1294eb31. [7] MENG SF, HUO Y, HOU TT, et al.Technical considerations on the quality control and nonclinical research for CAR-T cell therapy products[J]. Chinese Pharmaceutical Affairs(中国药事), 2018, 32(6): 829-852. [8] LI YH, HUO Y, YU L, et al.Quality control and nonclinical research on CAR-T cell products: general principles and key issues[J]. Engineering, 2019, 5(1): 263-283. [9] QU Z, LIN Z, HUO GT, et al.Risk assessment of tumorigenicity and oncogenicity of cell therapy product[J]. Chinese Journal of New Drugs(中国新药杂志), 2021, 30(19): 1819-1824. [10] SATO Y, BANDO H, DI PIAZZA M, et al.Tumorigenicity assessment of cell therapy products: the need for global consensus and points to consider[J]. Cytotherapy, 2019, 21(11): 1095-1111. [11] WEI Z, LYU S, WANG Y, et al.Biological characteristics of side population cells in a self-established human ovarian cancer cell line[J]. Oncol Lett, 2016, 12(1): 41-48. [12] WEI ZT, YU XW, HE JX, et al.Characteristics of primary side population cervical cancer cells[J]. Oncol Lett, 2017, 14(3): 3536-3544. [13] XIE T, MO L, LI L, et al.Identification of side population cells in human lung adenocarcinoma A549 cell line and elucidation of the underlying roles in lung cancer[J]. Oncol Lett, 2018, 15(4): 4900-4906. [14] ZHANG KH, JIA CC, WU XL, et al.Growth Factors in a culture medium may enhance tumorigenic potency of human mesenchymal stem cells[J]. Chinese Medicinal Biotechnology(中国医药生物技术)2021, 16(6): 481-491. [15] KUSAKAWA S, YASUDA S, KURODA T, et al.Ultra-sensitive detection of tumorigenic cellular impurities in human cell-processed therapeutic products by digital analysis of soft agar colony formation[J]. Sci Rep, 2015, 5: 17892. [16] QIN SQ, KUSUMA GD, AL-SOWAYAN B, et al.Establishment and characterization of fetal and maternal mesenchymal stem/stromal cell lines from the human term placenta[J]. Placenta, 2016, 39: 134-146. [17] MATHENI C, DSOUZA W.Xeno-free human Wharton's jelly mesenchymal stromal cells maintain their characteristic properties after long-term cryopreservation[J]. Cell J, 2021, 23(2): 145-153. [18] ZHENG GF, XIE CF, XU SK, et al.Clony formation capability of human umbilical cord-derived mesenchymal stem cell in soft agar and its effects on tumor cell proliferation in vitro[J]. Chinese Journal of Cell and Stem Cell (Electronic Edition)(中华细胞与干细胞杂志(电子版)), 2016, 6(2): 97-104. [19] QIN NS, GUO J, WANG X, et al.Tumor suppression effect and tumorigenicity of drugs evaluated by soft agar colony formation assay[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2017, 37(3): 444-450. |